EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

Luis C Bertot, Gary P Jeffrey, Bastiaan de Boer, Zhengyi Wang, Yi Huang, George Garas, Gerry MacQuillan, Michael Wallace, Briohny W Smith, Leon A Adams

Digestive Diseases and Sciences · 2023

DOI: 10.1007/s10620-023-07896-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2023. Verfasst von Luis C Bertot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Western Australia, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Western Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-invasive tests are widely used to diagnose fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), however, the optimal method remains unclear. We compared the accuracy of simple serum models, a serum model incorporating direct measures of fibrogenesis (Hepascore), and Fibroscan®, for detecting fibrosis in NAFLD. METHODS: NAFLD patients undergoing liver biopsy were evaluated with Hepascore, NAFLD Fibrosis Score (NFS), FIB-4 and AST-platelet ratio index (APRI), with a subset (n = 131) undergoing Fibroscan®. Fibrosis on liver biopsy was categorized as advanced (F3-4) or cirrhosis (F4). Accuracy was determined by area under receiving operating characteristic curves (AUC). Indeterminate ranges were calculated using published cut-offs. RESULTS: In 271 NAFLD patients, 83 (31%) had F3-4 and 47 (17%) cirrhosis. 6/131 (4%) had an unreliable Fibroscan®. For the detection of advanced fibrosis, the accuracy of Hepascore (AUC 0.88) was higher than FIB-4 (0.73), NFS (0.72) and APRI (0.69) (p < 0.001 for all). Hepascore had similar accuracy to Fibroscan® (0.80) overall, but higher accuracy in obese individuals (0.91 vs 0.80, p = 0.001). Hepascore more accurately identified patients with cirrhosis than APRI (AUC 0.85 vs 0.71, p = 0.01) and NFS (AUC 0.73, p = 0.01) but performed similar to FIB-4 and Fibroscan®. For the determination of F3-4, the proportion of patients in indeterminate area was lower for Hepascore (4.8%), compared to FIB-4 (42%), NFS (36%) and APRI (44%) (p < 0.001 for all). CONCLUSIONS: Hepascore has greater accuracy and a lower indeterminate range than simple serum fibrosis tests for advanced fibrosis in NAFLD, and greater accuracy than Fibroscan® in obese individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansLiverSeverity of Illness IndexLiver CirrhosisFibrosisBiomarkersObesityBiopsyAspartate Aminotransferases

Stichwörter der Autor:innen

DiagnosisElastographyLiver biopsyNon-invasive fibrosis modelsNonalcoholic fatty liver diseaseNonalcoholic steatohepatitis

Substanzen

BiomarkersAspartate Aminotransferases

Autor:innen und Institutionen

  • Medical School, University of Western Australia, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
  • Department of Hepatology, Sir Charles Gairdner Hospital, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
  • Department of Anatomical Pathology, Pathwest, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
  • Medical School, University of Western Australia, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia. leon.adams@uwa.edu.au.
  • Department of Hepatology, Sir Charles Gairdner Hospital, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia. leon.adams@uwa.edu.au.

Förderung

  • University of Western Australia

Zitieren

APA

Bertot, L. C., Jeffrey, G. P., de Boer, B., Wang, Z., Huang, Y., Garas, G., MacQuillan, G., Wallace, M., Smith, B. W., & Adams, L. A. (2023). Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-023-07896-3

Vancouver

Bertot LC, Jeffrey GP, de Boer B, Wang Z, Huang Y, Garas G, et al. Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences. 2023. doi:10.1007/s10620-023-07896-3

BibTeX
@article{Bertot2023,
  author = {Bertot, Luis C and Jeffrey, Gary P and de Boer, Bastiaan and Wang, Zhengyi and Huang, Yi and Garas, George and MacQuillan, Gerry and Wallace, Michael and Smith, Briohny W and Adams, Leon A},
  title = {Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease},
  journal = {Digestive Diseases and Sciences},
  year = {2023},
  doi = {10.1007/s10620-023-07896-3}
}
Kostenlos starten →